CHARACTERISTICS OF THE VASORELAXING ACTION OF (3E)-4-ETHYL-2-HYDROXIMINO-5-NITRO-3-HEXAMIDE FK409, A NEW VASODILATOR ISOLATED FROM MICROBIAL SOURCES, IN ISOLATED RABBIT ARTERIES

被引:15
作者
SHIBATA, S
SATAKE, N
SATO, N
MATSUO, M
KOIBUCHI, Y
HESTER, RK
机构
[1] TEXAS A&M UNIV SYST, COLL MED, DEPT MED PHARMACOL & TOXICOL, COLLEGE STN, TX 77843 USA
[2] FUJISAWA PHARMACEUT CO LTD, RES LABS, OSAKA 532, JAPAN
关键词
D O I
10.1097/00005344-199103000-00022
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We examined the vasoinhibitory effect of (3E)-4-ethyl-2-hydroximino-5-nitro-3-hexamide FK409, a new vasodilator, on contractile responses in isolated rabbit arteries. FK409 (10(-8)-10(-5) M) inhibited contractile responses to norepinephrine (NE), histamine (His), and 5-hydroxytryptamine (5-HT) in rabbit aorta. The pattern of inhibition by FK409 was not competitive. The inhibitory effect of FK409 on the 5-HT response was much greater than that of nitroglycerin (NG). A high concentration of FK409 (10(-5) M) was necessary to inhibit the response to KCl (10-70 mM). The effect of combined treatment with FK409 (10(-5) M) and a subthreshold concentration of nifedipine (10(-9) M) on the KCl response was much greater than a single treatment with either agent. In addition, 3 x 10(-6) M D600, but not FK409 (10(-6) or 10(-5) M), inhibited the increase in the rate of Ca-45 influx stimulated by a 40-mM KCl substituted solution. In a Ca2+-free medium containing EGTA and nifedipine, FK409 (10(-9)-10(-5) M) inhibited phasic responses to NE, His, and 5-HT, and subsequent sustained responses owing to addition of Ca2+. The response to caffeine in rabbit iliac arteries incubated in Ca2+-free medium was also inhibited by FK409 (10(-6) and 10(-5) M). In rabbit aorta precontracted with NE (10(-5) M) and partially inhibited by prior exposure to NG (10(-5) M), the relaxing effect of FK409 was slightly attenuated. Pretreatment of tissues with FK409 (10(-6) M) inhibited the relaxing action of NG much more than prior NG inhibited the relaxing action of FK409. Methylene blue (10(-5) M), but not hemoglobin (10(-6) M), inhibited the relaxing action of FK409, whereas M&B 22,948 (3 x 10(-4) M) potentiated it. FK409 caused a relaxation of precontracted aorta without endothelium that was inhibited by methylene blue. In rabbit aorta precontracted with NE, FK409 (10(-6) M) increased cyclic GMP but not cyclic AMP content. FK409 (10(-5) M) had no effect on the NE-mediated increase in tissue inositol monophosphate (IP). These results suggest that FK409 inhibits the responses attributed to both intracellular Ca2+ release and Ca2+ influx through receptor-operated channels. The inhibitory effect of FK409 on both the KCl contractile response and KCl-stimulated Ca-45 influx appears to be different from that of nifedipine or D600. Furthermore, the inhibitory action of FK409 may be partially mediated by cyclic GMP.
引用
收藏
页码:508 / 518
页数:11
相关论文
共 35 条
[1]  
ABDELLATIF AA, 1986, PHARMACOL REV, V38, P227
[2]  
ABDELLATIF AA, 1983, HDB NEUROCHEMISTRY, V3, P91
[3]   INOSITOL TRISPHOSPHATE, A NOVEL 2ND MESSENGER IN CELLULAR SIGNAL TRANSDUCTION [J].
BERRIDGE, MJ ;
IRVINE, RF .
NATURE, 1984, 312 (5992) :315-321
[4]  
BROWN SL, 1983, MOL PHARMACOL, V24, P351
[5]   EFFECT OF KT-362, A PUTATIVE INTRACELLULAR CALCIUM-ANTAGONIST, ON NOREPINEPHRINE-INDUCED CONTRACTIONS AND INOSITOL MONOPHOSPHATE ACCUMULATION IN CANINE FEMORAL-ARTERY [J].
ESKINDER, H ;
HILLARD, CJ ;
WILKE, RA ;
GROSS, GJ .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1989, 13 (03) :502-507
[6]  
GRUETTER CA, 1979, J CYCLIC NUCL PROT, V5, P211
[7]   METHYLENE-BLUE INHIBITS CORONARY ARTERIAL RELAXATION AND GUANYLATE-CYCLASE ACTIVATION BY NITROGLYCERIN, SODIUM-NITRITE, AND AMYL NITRITE [J].
GRUETTER, CA ;
KADOWITZ, PJ ;
IGNARRO, LJ .
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 1981, 59 (02) :150-156
[8]   NORADRENALINE CONTRACTIONS IN RABBIT MESENTERIC-ARTERIES SKINNED WITH SAPONIN [J].
HAEUSLER, G ;
RICHARDS, JG ;
THORENS, S .
JOURNAL OF PHYSIOLOGY-LONDON, 1981, 321 (DEC) :537-&
[9]  
HESTER RK, 1988, J PHARMACOL EXP THER, V247, P223
[10]  
HESTER RK, 1981, J PHARMACOL EXP THER, V216, P239